Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Background Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1). We report ≥2-year follow-up data for avelum...

Full description

Saved in:
Bibliographic Details
Main Authors: James L Gulley, Manish R Patel, Keun-Wook Lee, Luc Dirix, Mary Ruisi, Jeffrey R Infante, Patrick Schöffski, Alain Ravaud, Ding Wang, Andrea B Apolo, John A Ellerton, Manish Agrawal, Michael S Gordon, Raid Aljumaily, Theodore Gourdin, Matthew H Taylor, Juliane Manitz, Gregory Pennock
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001246.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001246.full

Similar Items